title: Ureaplasma parvum causes hyperammonemia in a pharmacologically immunocompromised murine model.
abstract: A relationship between hyperammonemia and Ureaplasma infection has been shown in lung transplant recipients. We have demonstrated that Ureaplasma urealyticum causes hyperammonemia in a novel immunocompromised murine model. Herein, we determined whether Ureaplasma parvum can do the same. Male C3H mice were given mycophenolate mofetil, tacrolimus, and prednisone for 7 days, and then challenged with U. parvum intratracheally (IT) and/or intraperitoneally (IP), while continuing immunosuppression over 6 days. Plasma ammonia concentrations were determined and compared using Wilcoxon rank-sum tests. Plasma ammonia concentrations of immunosuppressed mice challenged IT/IP with spent broth (median, 188 μmol/L; range, 102-340 μmol/L) were similar to those of normal (median, 226 μmol/L; range, 154-284 μmol/L, p > 0.05), uninfected immunosuppressed (median, 231 μmol/L; range, 122-340 μmol/L, p > 0.05), and U. parvum IT/IP challenged immunocompetent (median, 226 μmol/L; range, 130-330 μmol/L, p > 0.05) mice. Immunosuppressed mice challenged with U. parvum IT/IP (median 343 μmol/L; range 136-1,000 μmol/L) or IP (median 307 μmol/L; range 132-692 μmol/L) had higher plasma ammonia concentrations than those challenged IT/IP with spent broth (p < 0.001). U. parvum can cause hyperammonemia in pharmacologically immunocompromised mice.
authors: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St S.W., Rochester, MN, 55905, USA.|Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.|Division of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, Sichuan, China.
authors: X
authors: X
authors: Wang
authors: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St S.W., Rochester, MN, 55905, USA.
authors: K E
authors: KE
authors: Greenwood-Quaintance
authors: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St S.W., Rochester, MN, 55905, USA.
authors: M J
authors: MJ
authors: Karau
authors: Division of Clinical Core Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors: D R
authors: DR
authors: Block
authors: Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
authors: J N
authors: JN
authors: Mandrekar
authors: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St S.W., Rochester, MN, 55905, USA.
authors: S A
authors: SA
authors: Cunningham
authors: Department of Transplant, Mayo Clinic, Jacksonville, FL, USA.
authors: J M
authors: JM
authors: Mallea
authors: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St S.W., Rochester, MN, 55905, USA. patel.robin@mayo.edu.|Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA. patel.robin@mayo.edu.
authors: R
authors: http://orcid.org/0000-0001-6344-4141
authors: R
authors: Patel
mesh_terms: D000368:Aged; D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D022124:Hyperammonemia / Q000473:pathology*; D016867:Immunocompromised Host; D008297:Male; D008809:Mice, Inbred C3H; D010949:Plasma / Q000737:chemistry; D014509:Ureaplasma / Q000254:growth & development*; D016869:Ureaplasma Infections / Q000150:complications*